Profile data is unavailable for this security.
About the company
SymBio Pharmaceuticals Limited is a Japan-based pharmaceutical company. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The Company develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The Company manufactures and sells medicines through domestic and foreign pharmaceutical companies. The Company's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.
- Revenue in JPY (TTM)1.31bn
- Net income in JPY-4.78bn
- Incorporated2005
- Employees108.00
- LocationSymBio Pharmaceuticals LtdToranomon 30 Mori Bldg.3-2-2, ToranomonMINATO-KU 105-0001JapanJPN
- Phone+81 354721125
- Fax+81 354723054
- Websitehttps://www.symbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MEDRx Co Ltd | 128.08m | -937.37m | 6.00bn | 22.00 | -- | 2.93 | -- | 46.81 | -18.25 | -18.25 | 2.38 | 34.52 | 0.0578 | 0.0891 | 4.48 | -- | -42.29 | -48.18 | -44.11 | -51.18 | 99.06 | 98.18 | -731.84 | -1,002.97 | 23.40 | -319.43 | -- | -- | -50.34 | 2.16 | -16.19 | -- | 16.00 | -- |
| Kohjin Bio Co Ltd | 5.07bn | 557.40m | 6.45bn | 167.00 | 11.57 | 1.09 | 6.82 | 1.27 | 109.06 | 109.06 | 992.83 | 1,157.47 | 0.5768 | 3.51 | 4.58 | 30,386,960.00 | 6.34 | -- | 8.73 | -- | 43.01 | -- | 10.98 | -- | 1.49 | -- | 0.2443 | -- | 9.14 | -- | 106.44 | -- | -- | -- |
| Nippon Chemiphar Co Ltd | 32.52bn | 545.00m | 7.58bn | 855.00 | 11.78 | 0.3351 | 3.70 | 0.2331 | 151.00 | 151.00 | 9,009.80 | 5,309.46 | 0.6233 | 1.98 | 2.75 | 38,035,090.00 | 1.04 | 0.6794 | 1.44 | 0.9686 | 26.19 | 28.43 | 1.68 | 1.04 | 1.34 | -- | 0.4785 | 55.16 | 5.93 | 0.5075 | 263.33 | -7.58 | 32.85 | 0.00 |
| CellSource Co Ltd | 3.71bn | 10.66m | 7.88bn | 148.00 | 793.46 | 1.31 | 37.72 | 2.12 | 0.5003 | 0.5003 | 186.84 | 303.58 | 0.5265 | 5.91 | 11.31 | 25,077,400.00 | 0.1512 | 10.68 | 0.1613 | 11.89 | 56.24 | 64.88 | 0.2872 | 14.37 | 11.79 | 16.09 | 0.0093 | 20.88 | -14.78 | 14.87 | -95.52 | -47.76 | 8.90 | -- |
| COSMO BIO COMPANY, LIMITED | 10.77bn | 337.00m | 8.29bn | 174.00 | 23.18 | 0.8299 | 16.55 | 0.7702 | 59.14 | 59.14 | 1,893.02 | 1,651.94 | 0.883 | 6.53 | 3.57 | -- | 2.74 | 4.41 | 3.24 | 5.24 | 34.39 | 35.52 | 3.10 | 4.88 | 4.46 | -- | 0.002 | 50.68 | 7.26 | 5.88 | 28.63 | -12.94 | 34.02 | 8.02 |
| Solasia Pharma KK | 429.00m | -876.00m | 9.30bn | 23.00 | -- | 5.11 | -- | 21.67 | -3.79 | -3.79 | 1.81 | 6.65 | 0.2447 | 1.84 | 2.13 | -- | -49.96 | -64.76 | -58.36 | -79.60 | 48.48 | 58.61 | -204.20 | -297.25 | 5.70 | -61.50 | 0.0514 | -- | 35.76 | -1.13 | 54.87 | -- | -- | -- |
| K Pharma Inc | 0.00 | -993.23m | 10.00bn | 17.00 | -- | 7.89 | -- | -- | -85.59 | -85.59 | 0.00 | 109.00 | 0.00 | 0.00 | -- | -- | -37.53 | -- | -38.74 | -- | -- | -- | -- | -- | 28.29 | -1,982.81 | 0.5424 | -- | -- | -- | -17.34 | -- | -- | -- |
| Symbio Pharmaceuticals Ltd | 1.31bn | -4.78bn | 10.13bn | 108.00 | -- | 6.87 | -- | 7.74 | -95.49 | -95.49 | 26.04 | 21.39 | 0.296 | 1.37 | 3.83 | -- | -108.11 | -19.84 | -140.91 | -24.15 | 72.45 | 74.71 | -365.25 | -26.66 | 2.74 | -44.43 | 0.6092 | -- | -46.69 | -15.23 | -24.59 | -- | -11.15 | -- |
| Wakamoto Pharmaceutical Co Ltd | 9.29bn | 298.60m | 11.25bn | 286.00 | 37.54 | 0.9271 | 15.19 | 1.21 | 8.60 | 8.60 | 267.77 | 348.39 | 0.6006 | 1.62 | 3.06 | 32,493,160.00 | 1.93 | -0.0678 | 2.22 | -0.0781 | 47.70 | 48.65 | 3.21 | -0.1246 | 2.42 | -- | 0.0082 | -- | 0.6595 | -6.53 | -40.86 | -- | 21.87 | -- |
| CellSeed Inc | 83.68m | -1.10bn | 13.29bn | 38.00 | -- | 9.73 | -- | 158.80 | -31.83 | -31.83 | 2.41 | 35.67 | 0.0409 | 0.6561 | 3.81 | -- | -54.00 | -46.88 | -59.08 | -50.95 | 51.09 | 53.64 | -1,319.46 | -593.85 | 5.81 | -- | 0.0949 | -- | -56.71 | -15.95 | -28.41 | -- | 21.04 | -- |
| Immuno-Biological Laboratories Co., Ltd. | 1.03bn | 363.89m | 15.04bn | 58.00 | 41.33 | 8.53 | 39.35 | 14.58 | 39.07 | 39.07 | 110.76 | 189.25 | 0.5456 | 0.8603 | 4.81 | 17,786,030.00 | 19.25 | -4.96 | 22.46 | -5.77 | 70.35 | 62.70 | 35.27 | -11.27 | 3.96 | 2,702.08 | 0.0947 | -- | 18.71 | 10.95 | 33.40 | -- | -- | -- |
| TAIKO PHARMACEUTICAL CO LTD | 6.40bn | 923.00m | 15.09bn | 214.00 | 16.22 | 1.76 | 12.69 | 2.36 | 18.37 | 18.37 | 127.34 | 169.51 | 0.5080 | 1.77 | 2.62 | -- | 7.34 | -18.99 | 9.32 | -24.04 | 54.42 | 40.20 | 14.44 | -46.31 | 2.72 | -- | 0.0874 | -- | 1.67 | -- | 2.78 | -- | -- | -- |
Data as of Mar 04 2026. Currency figures normalised to SymBio Pharmaceuticals Ltd's reporting currency: Japanese Yen JPY
0.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Evolution Capital Management LLCas of 18 Feb 2026 | 200.00k | 0.33% |
Data from 18 Feb 2026 - 18 Feb 2026Source: FactSet Research Systems Inc.
